To describe progression-free survival of patients treated by subsequent chemotherapy following PARPi exposure in relapsing high-grade ovarian cancer defined as time to second progression (the time between first progression to second progression or death)
a. To describe overall survival of patients treated by subsequent chemotherapy following PARPi exposure in relapsing high-grade ovarian cancer b. To describe progression-free and overall survivals of patients treated by subsequent chemotherapy following PARPi exposure in relapsing high-grade ovarian cancer defined as time to second progression (the time between first progression to second progression or death) in the following subgroups: • BRCA1/2 mutated population • HRD population • BRCA1/2 negative, HRP negative population • BRCA ½ negative and HRD status unknown c. To describe the prognosis of patients following PARPi progression by evaluating Overall survival
Institut de Cancérologie de l'Ouest
Patientes atteintes d'une tumeur de l'ovaire
6.1.e) RGPD le traitement est nécessaire à l'exécution d'une mission d'intérêt public
Institut de cancérologie de l'Ouest
Conservation pendant 2 ans après la valorisation (publication/article, these, présentation orale, poster, autre) des résultats de la recherche. Puis archivage avec un accès restreint aux personnes intervenant dans la recherche, pendant une durée limitée de 3 ans (5ans au total post publication)